42 articles
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
A landmark 2025 review maps every mechanism behind arterial stiffness—and charts a clear path toward prevention and therapy.
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology — not individual diseases — may be medicine's biggest leap.
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
A 2025 review maps the pathophysiology of CRHM syndrome and spotlights emerging biomarkers that could transform early detection and treatment.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
A comprehensive review reveals mitochondrial quality control failures precede kidney damage in diabetes, spotlighting emerging drug targets.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
Reverse network pharmacology pinpoints berberine as a promising treatment for CKM syndrome, validated in a novel mouse model combining metabolic and cardiac stress.
A comprehensive 2026 review reveals how gut microbial dysbiosis fuels AKI and CKD progression—and how targeted microbiome therapies may reverse it.
